Ropes & Gray advised South Korea-based SK Biopharmaceuticals in a research and development collaboration with Insilico Medicine to discover AI-enabled drug candidates in neuroimmune disorders of the central nervous system in a deal worth up to $2.5 billion. The transaction was announced on June 22.
Insilico will leverage its Pharma.AI platform to discover, design and optimize novel drug candidates for neuroimmune indications. SK Biopharmaceuticals will lead late-stage development and commercialization of all resulting programs.
Under the agreement, Insilico will be eligible to receive up to $18 million in upfront and near-term milestone payments. The total potential deal value exceeds $2.5 billion including development, regulatory and commercial milestone payments, as well as royalties on net sales upon commercialization.
The Ropes & Gray team included IP transactions partner David McIntosh, counsel Joshua Talicska and associate Paul Matheke.
Stay Up To Date with Ropes & Gray
Ropes & Gray attorneys provide timely analysis on legal developments, court decisions and changes in legislation and regulations.
Stay in the loop with all things Ropes & Gray, and find out more about our people, culture, initiatives and everything that’s happening.
We regularly notify our clients and contacts of significant legal developments, news, webinars and teleconferences that affect their industries.